TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03254017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral surgical implantation of DBS system to Habeluna
Description: The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up Period
Description: The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
Study: NCT02940054

Intervention type: OTHER
Intervention: Red-flags questionnaire
Description: A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
Study: NCT01358500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intravenous infusion using STANPUMP
Study: NCT00766441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphonylurea
Description: sulphonylurea, variable, od or bd, during ramadan
Study: NCT03593941

Intervention type: OTHER
Intervention: Standard Diet
Description: Participants will consume the standard diet provided in care home

Intervention type: OTHER
Intervention: Standard Diet
Description: Participants will consume the standard diet provided in care home

Intervention type: OTHER
Intervention: Standard Diet
Description: Participants will consume the standard diet provided in care home
Study: NCT02431520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-collection
Description: Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gynecologist collection
Description: Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
Study: NCT02075970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alpha
Description: Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epoetin Alpha
Description: Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1.
Study: NCT02922712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NISE
Description: Nise 200mg Max per day in 2 divided doses
Study: NCT00653705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt drink with probiotic bacteria BB12
Description: Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vanilla flavored dairy drink. One bottle a day for 16 weeks.
Study: NCT03791424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administering premedication with sedative drug to relieve anxiety

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administering premedication with sedative drug to relieve anxiety
Study: NCT01872754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: Remifentanil
Description: 1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2: Propofol
Description: 2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
Study: NCT04130425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hely & Weber MTC Fracture Brace
Description: Prefabricated muenster orthosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoplastic orthosis
Description: Muenster orthosis fabricated out of thermoplastics and secured with Velcro

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta cast orthosis
Description: Muenster orthosis fabricated out of Delta Cast and secured with Velcro
Study: NCT02075970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotinylated Red Blood Cells
Description: Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
Study: NCT05222243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct pulp capping with calcium hydroxide
Description: Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct pulp capping with MTA
Description: Capping exposed dental pulps during cavity preparation in primary teeth with MTA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct pulp capping with Formocresol
Description: Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
Study: NCT03242070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theory-based PP eLearning Program(T-PeP)
Description: Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program.
Study: NCT04166227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroscopy
Description: Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
Study: NCT01225536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 736
Description: Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
Study: NCT00870324

Intervention type: DEVICE
Intervention: OptiSense Lead
Description: The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead.
Study: NCT01769222

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo local radiation therapy, 10 Gy x 3 fractions
Study: NCT03893617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acute stress task
Description: Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute stress task
Description: Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No stress task
Description: Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No stress task
Description: Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
Study: NCT00483145

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed dye laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
Study: NCT00057941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given intramuscularly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00380588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 milligrams per square meter (mg/m2), intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 milligrams per square meter (mg/m2), intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 25 milligrams per square meter (mg/m2), intravenous (IV)
Study: NCT01989884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortataxel
Description: 75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03539926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lit-control®pH Meter
Description: Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Reactive strips
Description: Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
Study: NCT01942616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Condition 1: Perpetrator Positive
Description: Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Condition 2: Perpetrator Negative
Description: The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Condition 3: Placebo
Description: This intervention provides no details for the participant and is for comparison use in the study.
Study: NCT01526135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfirinox
Description: mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
Study: NCT03672240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
Study: NCT03401281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil
Description: 50g extra virgin coconut oil daily for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: 50g butter daily for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 50g extra virgin olive oil daily for four weeks
Study: NCT01742208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo-matching sotagliflozin tablets once daily for 29 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
Study: NCT00818298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprazidone
Description: Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
Study: NCT04642781

Intervention type: DIAGNOSTIC_TEST
Intervention: reading of a text
Description: Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
Study: NCT02169752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ambrisentan
Description: Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner.
Study: NCT00715676

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP001
Description: oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP001
Description: oral, once daily
Study: NCT02667951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A home-based caregiver-training program
Description: A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
Study: NCT01529554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: (d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
Study: NCT03888235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate corrective exercises
Description: The sacroiliac forward flexion test (SIFFT) finds the position of each innominate bone. Subjects learn 1 of 3 exercises. To correct anterior rotation, flex the thigh hard against the ilium, pushing it backwards. To correct posterior rotation, hyperextend the thigh to pull the ilium forward. 1.Genuflect, anterior foot and posterior knee on the floor hands on the floor on either side of the foot, sliding the knee backwards to hyperextend the thigh. 2. Supine, anterior foot on an assistant's sternum, posterior thigh hyperextended. Assistant leans forward, forcing the anterior thigh against the ilium and pushing down on the posterior thigh. 3. For anterior rotation alone: anterior foot on a chair seat, pulling up hard with both hands, leaning back, forcing the thigh against the ilium. Hold position for 2 minutes. Use as needed for pain control. They are reassessed one month later when they receive the pelvic support belt. Both treatments used together will be assessed one month after.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate use of pelvic support belt
Description: Participants will be given a pelvic support belt to stabilize their sacroiliac joints. The belt is fitted tightly around the pelvis, over the sacrum and below the anterior superior iliac spines (ASISs) to prevent opening the joint. (The upper part of the innominate bones flares out so pushing them inwards will move the lower part outwards, away from the sacrum, opening the sacroiliac joints, increasing their instability). They will use this belt for activities which have in the past precipitated back pain. They will be reassessed one month later.~At that time they will be given the exercises to correct their sacroiliac malrotation and the concurrent use of both treatments will be assessed at their last visit one month later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed treatment
Description: Participants will continue the treatments they are currently using to relieve their low back pain for one month. At their one-month visit, they will be taught how to assess the direction of sacroiliac malrotation and how to do the corrective exercise. They will also be fitted for a pelvic stabilization belt.
Study: NCT01476904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg/inhalation, 2 inhalations QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primatene Mist
Description: 220 mcg/inhalation, 2 inhalations QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine inhalation
Description: 125 mcg/inhalation, 2 inhalations QID
Study: NCT00870324

Intervention type: DEVICE
Intervention: Tendril Lead
Description: The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead.
Study: NCT03734458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A - PRF plus AFG with a CAF
Description: Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B - PRF only with a CAF
Description: Group B - PRF only with a CAF will be used surgically to cover the exposed roots.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C - CTG with a CAF
Description: Group C - CTG with a CAF will be used surgically to cover the exposed roots.